Hairy cell leukemia surgery: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hairy cell leukemia}} | {{Hairy cell leukemia}} | ||
{{CMG}} {{AE}}{{HL}} | {{CMG}}; {{AE}} {{HL}} {{VKG}} | ||
==Overview== | ==Overview== | ||
Revision as of 15:09, 26 November 2018
|
Hairy cell leukemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hairy cell leukemia surgery On the Web |
|
American Roentgen Ray Society Images of Hairy cell leukemia surgery |
|
Risk calculators and risk factors for Hairy cell leukemia surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2] Vamsikrishna Gunnam M.B.B.S [3]
Overview
The predominant therapy for hairy cell leukemia is chemotherapy. Surgical management, such as splenectomy, may be required in certain cases.
Surgery
The predominant therapy for hairy cell leukemia is chemotherapy. Surgical management, such as splenectomy, may be required in certain cases.[1]
References
- ↑ Robak T (August 2006). "Current treatment options in hairy cell leukemia and hairy cell leukemia variant". Cancer Treat. Rev. 32 (5): 365–76. doi:10.1016/j.ctrv.2006.04.010. PMID 16781083.